D-amphetamine compounds, compositions, and processes for making and using the same

A method of treating a patient having a disorder or condition requiring stimulation of the central nervous system, of treating a patient having a disease, disorder, or condition mediated by increasing neurotransmitter concentrations in the synapse, the method comprising the step of administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:

• a compound has the structure of Formula II
• where X is selected from the group consisting of esters, carboxylic acids, amino acids, and
• Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
• or a pharmaceutically acceptable salt of said compound;
• and
• wherein the disease or condition is attention-deficit hyperactivity disorder, attention deficit disorder, autistic spectrum disorder, autism, Asperger's disorder, pervasive developmental disorder, sleep disorder, bipolar disorder, eating disorder, chronic fatigue syndrome, insomnia, major depressive disorder, narcolepsy, postural orthostatic tachycardia syndrome, substance use disorder, lethargy, depression, neural insult or obesity, and
• wherein the compound having a structure of Formula II is a prodrug of d-amphetamine.

A method of treating a patient having a disorder or condition requiring stimulation of the central nervous system, of treating a patient having a disease, disorder, or condition mediated by increasing neurotransmitter concentrations in the synapse, the method comprising the step of administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:

• a compound having the structure of Formula III:
• where X is selected from the group consisting of esters, carboxylic acids, amino acids, amino acid residues, amides, and derivatives thereof, wherein when X is an amide, at least one amide substituent is hydrogen, or at least one amide substituent comprises at least two carbons,
• and Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
• or a pharmaceutically acceptable salt thereof;
• and
• wherein the disease or condition is attention-deficit hyperactivity disorder, attention deficit disorder, autistic spectrum disorder, autism, Asperger's disorder, pervasive developmental disorder, sleep disorder, bipolar disorder, eating disorder, chronic fatigue syndrome, insomnia, major depressive disorder, narcolepsy, postural orthostatic tachycardia syndrome, substance use disorder, lethargy, depression, neural insult or obesity, and
• wherein the compound having a structure of Formula III is a prodrug of d-amphetamine.

A method of treating a patient having a disease or condition, the method comprising the step of:

• administering to the patient in need thereof a pharmaceutically effective amount of a composition comprising:
• a compound having the structure of Formula I:
• where X is selected from the group consisting of esters, carboxylic acids, amino acids, amino acid residues, amides, and derivatives thereof, and
• Y is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, alkynyl, aryl, substituted aryl, alkylaryl, cycloalkenyl, cycloalkyl, cycloalkynyl, heteroalkyl, heteroaryl, and heterocycle;
• or a pharmaceutically acceptable salt of said compound;
• wherein the disease or condition is attention-deficit hyperactivity disorder, attention deficit disorder, autistic spectrum disorder, autism, Asperger's disorder, pervasive developmental disorder, sleep disorder, bipolar disorder, eating disorder, chronic fatigue syndrome, insomnia, major depressive disorder, narcolepsy, postural orthostatic tachycardia syndrome, substance use disorder, lethargy, depression, neural insult or obesity, and
• wherein the compound having a structure of Formula I is a prodrug of d-amphetamine.